Triglütideks

Triglütideks refers to a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). These medications are primarily used to manage type 2 diabetes and, in some cases, obesity. Triglütideks work by mimicking the action of the natural hormone GLP-1, which is released in the gut after eating. This stimulation of GLP-1 receptors leads to several beneficial effects.

Firstly, triglütideks enhance insulin secretion from the pancreas in response to elevated blood glucose levels. This helps to lower blood sugar after meals. Secondly, they suppress glucagon secretion, another hormone that raises blood sugar. Thirdly, they slow gastric emptying, which can contribute to a feeling of fullness and reduce appetite, aiding in weight management. Triglütideks are typically administered through subcutaneous injection. Common side effects can include gastrointestinal issues such as nausea, vomiting, and diarrhea, though these often diminish over time. They are not recommended for individuals with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.